For Immediate Release: August 17, 2016
Medpace Continues to Expand Scientific Leadership Four Medical Directors Join Medpace’s Therapeutically-focused Teams
CINCINNATI, OH — (August 17, 2016) – Medpace (MEDP), a scientifically-driven, global full- service clinical contract research organization (CRO) known for its strong therapeutic and regulatory expertise, announced the addition of four physicians who will provide scientific and medical leadership in designing and conducting global clinical research. Medpace is pleased to welcome the following experts to the Medpace team:
Nicholas Alp, MD, PhD, FRCP, FACC – Cardiovascular
Dr. Alp joins an experienced team that has contributed to numerous cardiovascular NDAs and helped pioneer many of the preventative cardiovascular compounds and devices in the last 15 years. For more information regarding Medpace’s experience in cardiology, please click here.
Sarah DeRossett, MD, PhD – Neuroscience
Dr. DeRossett joins a team of highly experienced neurologists with broad experience across neurological, pain and psychiatric indications. Medpace has conducted Phase I-IV neuroscience trials around the globe. To learn more about Medpace’s neuroscience experience, please click here.
Hervé Momméja-Marin, MD – Infectious Diseases & Vaccines
Dr. Hervé Momméja-Marin joins a team of board-certified infectious disease physicians with backgrounds in academic hospitals, pharmaceutical companies and public health organizations. The Medpace team has broad experience in designing and conducting global Phase I-IV clinical trials in antivirals, antibacterials, antifungals and vaccines. To learn more about Medpace’e capabilities in infectious diseases and vaccines, please click here.
Alicia Weeks, MD – Endocrine and Metabolic
Dr. Weeks joins an international team of medical and regulatory experts who have helped pioneer many preventative metabolic compounds. With a successful track record of approvable NDA submissions, deep therapeutic expertise and more than 20 years of experience, Medpace successfully navigates the complexities and regulatory scrutiny of endocrine/metabolic development programs. For more information on Medpace’s experience in endocrine and metabolic, please click here.
The addition of these therapeutic experts further strengthens Medpace’s unique physician- driven clinical development model which gives Sponsors specialized expertise throughout the design and management of their program
About Nicholas Alp, MD, PhD, FRCP, FACC
Dr. Nicholas Alp is a board certified interventional cardiologist and clinician scientist with more than 25 years of clinical research experience. Dr. Alp trained in medicine at the University of London and the University of Oxford. He completed his PhD in Immunology at Cambridge University with a further post-doctoral DM degree in Vascular Biology at Oxford University. He held senior academic appointments in Cardiovascular Medicine at Oxford University, and as a consultant Interventional Cardiologist at Oxford Radcliffe Hospitals NHS trust. Prior to joining Medpace, Dr. Alp was Head of Cardiovascular Drug Development at a global Clinical Research Organization. He has authored more than 65 original papers, chapters and books, and has established himself as a thought leader in the industry.
About Sarah DeRossett, MD, PhD
Dr. Sarah DeRossett is a seasoned neurologist with a strong background in industry, clinical practice, and academia. She has had fifteen years of experience in clinical and academic medicine as well as a strong pharmaceutical career. Dr. DeRossett earned her medical degree from the Emory University School of Medicine in Atlanta, GA, as well as a PhD in Neural and Behavioral Studies from the University of Kentucky. She completed her residency in Neurology at The John Hopkins Hospital in Baltimore and is certified by the American Board of Psychiatry & Neurology. Dr. DeRossett worked as a Senior Medical Director for seven years and served as Vice President of Clinical Research and Medical Affairs prior to joining Medpace. Dr. DeRossett has been listed in Best Doctors in America for six consecutive years and received three awards for Excellence in Residency Training from the Emory University School of Medicine.
About Hervé Momméja-Marin, MD
Dr. Hervé Momméja-Marin is an internal medicine and infectious disease specialist with 15 years of clinical research experience working for both pharmaceutical companies and CROs. He received his medical degree from the University Pierre et Marie Curie in Paris France. He also earned degrees in biostatistics and epidemiology. At his previous companies, he acted as a project leader for numerous antivirals, antifungals, antibacterial, and vaccine programs in patient populations ranging from neonates to the elderly. He has designed and conducted numerous clinical trials from Phase I through IV, including expanded accesses, leading the regulatory interactions with FDA, EMA and multiple competent authorities/reimbursement bodies globally. He has contributed to multiple NDAs, MAAs and INDs.
About Alicia Weeks, MD
Dr. Alicia Weeks is an experienced clinical endocrinologist with both an academic clinical practice and a research-based position in the V.A. Hospital Advanced Women’s Fellowship Program. Dr. Weeks gained experience from a duel appointment as a clinical instructor at the University of Wisconsin Hospital & Clinics and as a Research Fellow at the William S. Middleton Memorial Veterans Hospital after earning her medical degree from the Wright State University Boonshoft School of Medicine. She is continuing her education at the University of Wisconsin School of Medicine and Public Health in the Master of Public Health Program where she is concentrating in epidemiology. Dr. Weeks completed her residency at the Kettering Medical Center and an endocrinology fellowship at the University of Wisconsin. There she was awarded the Dickie Research Award for her significant research contribution toward advancing the field of medicine.
Medpace is a scientifically-driven, global full-service clinical contract research organization (CRO) providing Phase I-IV clinical development services for drug, biologic, and device programs. Medpace’s physician-led, high-science, and disciplined operating approach leverages regulatory and therapeutic expertise to accelerate the global development of safe and effective medical therapeutics across all major areas including oncology, cardiovascular, metabolic/diabetes, infectious disease, and neuroscience. Headquartered in Cincinnati, Ohio, Medpace employs approximately 2,500 people worldwide with operations in 35 countries.
For more information, please visit www.medpace.com